Document Detail

Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
MedLine Citation:
PMID:  20679886     Owner:  NLM     Status:  MEDLINE    
Pegylated liposomal doxorubicin (PLD; Doxil or Caelyx) has been shown to be as effective as conventional doxorubicin, and to have a significantly better cardiac safety profile. The aim of this study was to assess the safety of delivering doses exceeding 700 mg/m of PLD to patients with solid tumors. A review of the medical records of 149 patients with a variety of solid tumors treated with PLD was performed. The findings in 12 patients who had reached or exceeded cumulative doses of 700 mg/m (median=1.071 mg/m, range 712-1856 mg/m) were reviewed. Changes in left ventricular ejection fraction (LVEF), and in clinical cardiac status were analyzed. The median age of the patients was 53.9 years and the median follow-up from the start of PLD treatment was 44.6 months. None of the 12 patients had clinical congestive heart failure secondary to cardiomyopathy. Seven of the 12 patients underwent further assessment of LVEF by echocardiography or multiple gated acquisition scan, which revealed a stable or improved ejection fraction.PLD is cardiac safe for long-term treatment of metastatic solid tumors. Its maximal cumulative dose remains undefined. Frequent determinations of LVEF, as routinely done for other anthracyclines, do not appear to have any clinical value in patient follow-up. In metastatic patients with no evidence of cardiac risk factors, it may be sufficient to measure LVEF at baseline.
Tal Grenader; Anthony Goldberg; Alberto Gabizon
Related Documents :
10744796 - Prolonged distress and clinical deterioration before pericardial drainage in patients w...
16100176 - Cardioprotective effects of acute normovolemic hemodilution in patients undergoing coro...
12212366 - Severe accidental hypothermia with or without hemodynamic instability: rewarming withou...
2298706 - The effect of nortriptyline in elderly patients with cardiac conduction disease.
15181966 - Nocturnal enuresis in older adults.
21741276 - Long-term outcome of epilepsy in kabuki syndrome.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  21     ISSN:  1473-5741     ISO Abbreviation:  Anticancer Drugs     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-02     Completed Date:  2010-12-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  868-71     Citation Subset:  IM    
Department of Oncology, Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / administration & dosage,  adverse effects*,  therapeutic use
Dose-Response Relationship, Drug
Doxorubicin / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Drug Monitoring / methods
Follow-Up Studies
Middle Aged
Neoplasms / drug therapy*,  pathology
Polyethylene Glycols / administration & dosage,  adverse effects*,  therapeutic use
Retrospective Studies
Time Factors
Ventricular Function, Left / drug effects
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Polyethylene Glycols; 0/pegylated liposomal doxorubicin; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Epithelial-Myoepithelial Carcinoma With High Grade Transformation.
Next Document:  Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?